Glucagonoma: Still a Misleading Disease and the Importance of Multidisciplinary Neuroendocrine Tumor Board Abstract #2775

Introduction: Glucagonoma is a rare neuroendocrine tumor (NET) of the pancreatic alpha cells that results in the overproduction of the hormone glucagon. This entity is typically associated with a rash called necrolytic migratory erythema, weight loss and diabetes.
Aim(s): To underline the potentially severe consequences of the delay in the diagnosis of a rare disease.
Materials and methods: Case report.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Anna La Salvia

To read results and conclusion, please login ...

Further abstracts you may be interested in

#996 Good Clinical Response to a Somatostatin Analog in a Patient with Metastatic Glucagonoma and Necrolytic Migratory Erythema: 5-Year Follow-Up
Introduction: Glucagonoma is a rare neuroendocrine tumor of the pancreas usually diagnosed in advanced stages or when necrolytic migratory erythema occurs.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Lisseth F Marín
#2955 Development of an EORTC Quality of Life Questionnaire for Patients with Pancreatic Neuroendocrine Tumours: Phases 1-3
Introduction: Measuring quality of life (QoL) in Pancreatic Neuroendocrine Tumours (pNET) involves assessing issues from symptoms, disease and treatment. The validated gastrointestinal NETs module (EORTC QLQ-GINET21) is used with EORTC QLQ-C30 but there are concerns it inadequately measures QoL in pNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Elizabeth Friend
#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors
Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Yao J C, Beaumont J L, Choi S, Cella D, ...
#614 The Effect of Patient and Doctors Delay in Patients with Neuroendocrine Tumors
Introduction: The diagnosis of neuroendocrine tumors (NET) is often delayed due to the vague symptoms and rareness of the disease.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Catharina M Korse
#1108 Regression of Paraneoplastic Optic Neuropathy Associated with Glucagonoma After Surgical Resection
Introduction: Glucagonomas-associated ocular manifestations have been exceptionally reported.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Lucie Defour